Mechelen, Belgium, March 25, 2016 -- Today Galapagos NV (Euronext & NASDAQ: GLPG) has published its Annual Report for the financial year 2015.
The Annual Report for the financial year 2015, including a review of figures and performance, is available online on http://reports.glpg.com/annual-report-2015/en/ and can also be downloaded as PDF.
Furthermore, Galapagos has the honor to invite its Shareholders, Warrant Holders, Directors and Statutory Auditor to its Annual and Extraordinary Shareholders' Meetings that will be held on Tuesday 26 April 2016 at 2:00 p.m. (CET) at the registered office of the Company.
In order to be admitted to the Shareholders' Meetings, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code and article 29 of the Company's articles of association, and fulfill the formalities described in the convening notices. The convening notices and other documents pertaining to the Shareholders' Meetings can be consulted on our website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises three Phase 2, three Phase 1, five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contact
Galapagos NV
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Communications Director Communications
+1 781 460 1784 +31 6 53 591 999
[email protected] [email protected]
Forward-Looking Statements
This release may contain forward-looking statements. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. A list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on Form 20F filed with the SEC and other filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
Publication of AR and invitation for AGM http://hugin.info/133350/R/1997716/736508.pdf
HUG#1997716


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



